Verition Fund Management
CGEM icon

Verition Fund Management’s Cullinan Oncology CGEM Stock Holding History

Verition Fund Management’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-139,660
Closed -$1.05M – 3777
2025
Q2 		$1.05M Buy
139,660
+110,485
+379% +$888K ﹤0.01% 2434
2025
Q1 		$221K Buy
+29,175
New +$280K ﹤0.01% 3012
2024
Q4 		– Sell
-36,624
Closed -$613K – 3269
2024
Q3 		$613K Buy
+36,624
New +$650K ﹤0.01% 2197
2024
Q1 		– Sell
-112,873
Closed -$1.15M – 2792
2023
Q4 		$1.15M Sell
112,873
-96,976
-46% -$859K 0.01% 1105
2023
Q3 		$1.9M Sell
209,849
-11,262
-5% -$117K 0.02% 808
2023
Q2 		$2.38M Buy
+221,111
New +$2.35M 0.03% 603

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Verition Fund Management's CGEM Position: Q3 2025 in Review

Verition Fund Management sold out of Cullinan Oncology (CGEM) in Q3 2025, closing a stake of 139,660 shares — an estimated $1.05M sold.

Verition Fund Management first reported a position in CGEM in Q2 2023 and held it in 6 quarters. The position peaked at $2.38M in Q2 2023. 145 funds tracked by Wall St. Rank hold CGEM as of Q3 2025.

  • Verition Fund Management reported no remaining Cullinan Oncology position as of Q3 2025 after selling out during the quarter.
  • Verition Fund Management sold 139,660 Cullinan Oncology shares in Q3 2025, an estimated $1.05M.
  • Verition Fund Management first reported a position in Cullinan Oncology in Q2 2023 and held it in 6 quarters.
  • Verition Fund Management's Cullinan Oncology position peaked at $2.38M in Q2 2023.
  • 145 funds tracked by Wall St. Rank held Cullinan Oncology as of Q3 2025.

Based on Verition Fund Management's 13F filing for Q3 2025, filed 14 Nov 2025.